BioVie (BIVI) KOL event summary

Introduction and agenda

• Event focused on updates for two clinical trials: Parkinson's and long COVID, with a Q&A session at the end.

• Parkinson's trial is nearly complete, with data analysis expected by end of the current or next quarter.

• Long COVID trial is nearing last patient visit, with top-line data expected before the end of summer.

KOL background and credentials

• Dr. Suzanne de la Monte is a professor at Brown University, specializing in pathology, neurology, and neurosurgery, and is Chief of Pathology at the Providence VA Medical Center.

Market insights and analysis

• Neurodegenerative diseases like Alzheimer's and Parkinson's are increasing globally, with Alzheimer's projected to affect 115 million people by 2050.

• Non-motor symptoms of Parkinson's, such as depression, fatigue, and cognitive impairment, significantly impact quality of life and are often under-recognized.

• Current treatments focus on motor symptoms and do not adequately address non-motor symptoms or disease progression.